Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
2 hedge funds and large institutions have $8K invested in Acorda Therapeutics in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 15 closing their positions.
88% less funds holding
Funds holding: 17 → 2 (-15)
100% less capital invested
Capital invested by funds: $2.13M → $8K (-$2.13M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 15
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
-$689K |
| 2 |
Renaissance Technologies
New York
|
-$618K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$254K |
| 4 |
BlackRock
New York
|
-$80.7K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$49.4K |
ACOR Hedge Fund Activity: Q2 2024 in Review
2 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2024, worth a combined $8K — down 100% from $2.13M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ACOR and 0 opened new positions — a net loss of 15 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Davidson Kempner Capital Management, exiting entirely with an estimated $689K sold.
- 2 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2024, down from 17 in Q1 2024.
- Funds reported $8K of Acorda Therapeutics stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new Acorda Therapeutics positions in Q2 2024 and 15 closed out, a net change of -15 holders.
- The largest Acorda Therapeutics seller in Q2 2024 was Davidson Kempner Capital Management, an estimated $689K sold.
Based on aggregated 13F filings for Q2 2024.